Iambic Therapeutics (NASDAQ:IAM) Shares Gap Up – What’s Next?

Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) shares gapped up prior to trading on Wednesday. The stock had previously closed at $14.22, but opened at $15.00. Iambic Therapeutics shares last traded at $15.20, with a volume of 113,371 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IAM. Citigroup began coverage on shares of Iambic Therapeutics in a research note on Monday, November 9th. They set a “buy” rating and a $22.00 price objective for the company. JPMorgan Chase & Co. began coverage on Iambic Therapeutics in a report on Monday, November 9th. They issued an “overweight” rating and a $22.00 target price on the stock. Wall Street Zen upgraded Iambic Therapeutics to a “hold” rating in a report on Saturday, November 7th. Zacks Research assumed coverage on Iambic Therapeutics in a research report on Tuesday, November 10th. They set a “hold” rating for the company. Finally, Jefferies Financial Group assumed coverage on Iambic Therapeutics in a research note on Tuesday, November 10th. They set a “buy” rating and a $35.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.25.

View Our Latest Stock Report on Iambic Therapeutics

Iambic Therapeutics Price Performance

Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($6.23) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($5.90). The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $42.50 million. As a group, equities research analysts predict that Iambic Therapeutics, Inc. will post -1.79 earnings per share for the current year.

Insider Activity at Iambic Therapeutics

In related news, Director Evan Lockwood Rachlin bought 718,750 shares of the firm’s stock in a transaction dated Friday, October 16th. The stock was bought at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the completion of the transaction, the director directly owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. This represents a 38.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.90% of the stock is currently owned by corporate insiders.

Iambic Therapeutics Company Profile

(Get Free Report)

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

Featured Articles

Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.